[Adjuvant therapy with pseudomonas immunoglobulin in artificially ventilated patients at a surgical intensive care unit].
Preoperative hospitalism and postoperative respiratory therapy together with antibiotical prophylaxis are risk factors for pulmonary infection due to Pseudomonas aeruginosa. Psomaglobin, a new Pseudomonas hyperimmune globulin, was given to 25 postoperative or posttraumatic patients during a prospective randomized study as an additional therapy for severe Pseudomonas infection. Respiratory therapy and therefore residence in the ICU were markedly shorter in the therapy (n = 25) than in the control group (n = 20).
Class
I
I
Klinik für Anästhesiologie und Transfusmedizin, Eberhard-Karls-Universität Tübingen.
Schorer
R
R
D036002:ADP Ribose Transferases; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001427:Bacterial Toxins; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003422:Critical Care; D003428:Cross Infection / Q000517:prevention & control*; D005098:Exotoxins / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000517:prevention & control*; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology; D011897:Random Allocation; D012121:Respiration, Artificial; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D007074:Immunoglobulin G; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
Adjuvante Therapie mit Pseudomonas-Immunglobulin bei beatmeten Patienten einer operativen Intensivstation.